Search

Your search keyword '"Erol Göka"' showing total 122 results

Search Constraints

Start Over You searched for: Author "Erol Göka" Remove constraint Author: "Erol Göka"
122 results on '"Erol Göka"'

Search Results

2. Erkek alkol bağımlılığı hastalarında tedavi motivasyonu, bağımlılık özellikleri, aşerme ve mizaç özellikleri ilişkisi

3. Pregabalin abuse among patients with opioid use disorders may increase the severity of withdrawal symptoms: a single-center, case-control study

4. The severity of dissociative symptoms among patients with cannabis and synthetic cannabinoid use disorder: association with substance use characteristics and suicide

5. Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

6. Examination of formal thought disorder and its clinical correlates with the Turkish Version of the Thought and Language Disorder Scale (TALD-TR) in schizophrenia

7. Serum 15-d-PGJ2 and PPARγ levels are reduced in manic episode of bipolar disorder while IL-4 levels are not affected

8. The relationship between internalized stigma and treatment motivation, perceived social support, depression and anxiety levels in opioid use disorder

9. Oral Research Presentations

10. Symposium Oral Presentations

11. Serum glial cell line-derived neurotrophic factor levels and impulsivity in heroin addiction: a cross-sectional, case-control study of 129 heroin addicts

12. 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology

13. 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology

14. 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology

15. Reversible cycloplegia caused by duloxetine: a case report

17. Neuronal pentraxin-2 (NPTX2) serum levels during an acute psychotic episode in patients with schizophrenia

19. Association of Glial Cell-Line Derived Neurotrophic Factor and Nerve Growth Factor with Duration of Untreated Psychosis and Clinical Symptoms in Drug-Naive Schizophrenia

20. Low Anti-Mullerian Hormone Levels Are Associated with the Severity of Anxiety Experienced by Healthcare Professionals During the COVID-19 Pandemic

21. Serum concentrations of aminoacylase 1 in schizophrenia as a potential biomarker: a case-sibling-control study

22. The Social Effects of COVID-19 Pandemics

23. Evaluating the Relationship Between Post Traumatic Stress Disorder Symptoms and Psychological Resilience in a Sample of Turkoman Refugees in Turkey

24. Thiol/Disulfide Homeostasis in Bipolar and Unipolar Depression

25. Association between treatment motivation, addiction characteristics, craving and temperament traits in male patients with alcohol addiction

27. Evaluation of Anxiety, Burnout and Psychological Resilience Levels of Healthcare Workers in the COVID-19 Pandemic

28. Do Anxiety and Depression Levels Affect the Inflammation Response in Patients Hospitalized for COVID-19

29. Pregabalin abuse among patients with opioid use disorders may increase the severity of withdrawal symptoms: a single-center, case-control study

30. The severity of dissociative symptoms among patients with cannabis and synthetic cannabinoid use disorder: association with substance use characteristics and suicide

31. Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

32. Sexual functions and prolactin levels in patients with bipolar disorder

33. From predictions to evidence: Treatment compliance, disease progression and social compliance of patients with schizophrenia in the COVID‐19 pandemic

34. Comparison of Formal Thought Disorder in the Acute Episode of Schizophrenia and Manic Episode of Bipolar Affective Disorder

36. Retrospective Evaluation of Cases Examined to Determine Criminal Responsibilities

37. Correction to: Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings

38. Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups?

39. Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings

41. Brief psychotic disorder due to ephedrine

42. Evaluation of dsyfunctional attitudes, distress and discomfort tolerance levels in patients with premenstruel dysphoric disorder

43. Serum PGE2, 15d-PGJ, PPAR gamma and CRP levels in patients with schizophrenia

44. Serum 15-d-PGJ2 and PPARγ levels are reduced in manic episode of bipolar disorder while IL-4 levels are not affected

45. High neutrophil-lymphocyte ratio in schizophrenia independent of infectious and metabolic parameters

46. A case of generalized edema associated with risperidone monotherapy (tur)

47. Serum glial cell line-derived neurotrophic factor levels and impulsivity in heroin addiction: a cross-sectional, case-control study of 129 heroin addicts

48. Serum TNF-related weak inducer of apoptosis (TWEAK) and TNF-related apoptosis-inducing ligand (TRAIL) levels of patients with bipolar disorder in manic episode, in remission and healthy controls

49. [Effects of Nitric Oxide Synthase-1 Exon 1f-VNTR Gene Polymorphism on the Clinical Symptoms of Alcohol Dependence,Impulsivity and Comorbid Attention Deficit Hyperactivity Disorder]

50. Quality of life and pain perception in alcohol dependence: A comparative examination of patients, their relatives, and healthy controls

Catalog

Books, media, physical & digital resources